artemether/lumefantrine / Generic mfg. - LARVOL DELTA

Persistent parasitaemia after artemether/lumefantrine for uncomplicated malaria revealing incidental filarial coinfection: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease • Malaria

Geographical Heterogeneity in Antimalarial Resistance Markers by Genomic Surveillance in Angola, 2023. (PubMed, Am J Trop Med Hyg) - "Efficacy of artemether-lumefantrine has been reported below 90% in two provinces, underscoring the need for routine resistance surveillance...In the southeast, artemisinin partial resistance markers (k13 P574L, P441L) were detected at very low prevalence (35% of samples)...The chloroquine resistance marker crt C72/V73/M74I/N75E/K76T (CVIET) haplotype had a national prevalence of 17.7%, detected in over 48% of samples from the northern sites...Coinfections of P. falciparum and non-falciparum species were rare, with no Plasmodium vivax coinfections detected. These findings highlight the need for continued monitoring to safeguard treatment efficacy, reinforcing the importance of molecular surveillance in malaria control strategies."

Heterogeneity • Journal • Infectious Disease • Malaria • ABCB1 • DHFR

Targeted Genomic Surveillance Unveils Genetic Variations Linked to Regional Malaria Drug Resistance Dynamics in India. (PubMed, Open Forum Infect Dis) - "India's historical policy of artesunate-sulfadoxine-pyrimethamine in central India and artemether-lumefantrine in the Northeast has shaped contrasting resistance profiles. In the Northeast, chloroquine resistance persisted at high frequency (Pfcrt K76T and CVIET haplotype; Pfaat1 S258L), alongside quintuple and sextuple Pfdhfr-Pfdhps haplotypes conferring complete sulfadoxine-pyrimethamine resistance...India's resistance landscape is fragmented, with signals of expanding lumefantrine tolerance and importation or evolution of globally relevant mutations. These findings highlight the importance of integrating molecular genomic surveillance into malaria control policy to monitor and protect ACT effectiveness and advance malaria elimination."

Journal • Infectious Disease • Malaria • ABCB1

Efficacy, safety and tolerability of KLU156 in adults and children with uncomplicated P. falciparum malaria (clinicaltrialsregister.eu) - P3 | N=1720 | Sponsor: Novartis Pharma AG

New P3 trial • Infectious Disease • Malaria

Molecular markers of antimalarial drug resistance in pfk13, pfmdr1, pfdhfr, and pfdhps genes of Plasmodium falciparum in a rural municipality in Cubal, Benguela Province, Angola (2022-2023). (PubMed, Malar J) - "This study provides an updated molecular profile of antimalarial resistance in a rural area of Angola. No validated or candidate pfk13 markers of artemisinin resistance were identified. However, the predominance of pfmdr1 haplotypes linked to reduced lumefantrine susceptibility raises concerns regarding AL efficacy. Although SP remains suitable for IPTp, the presence of the "fully resistant" haplotype (IRNGE) of pfdhfr/pfdhps highlight potential risks to long-term effectiveness. These findings reinforce the need for integrated molecular surveillance and periodic therapeutic efficacy studies to guide malaria control policies in rural Angola."

Biomarker • Journal • Infectious Disease • Malaria • ABCB1

Severe Plasmodium falciparum Malaria Complicated by Post-artemisinin Delayed Hemolysis in a Non-immune Pediatric Returning Traveler. (PubMed, Cureus) - "He developed multiorgan dysfunction, including thrombocytopenia, acute kidney injury, hepatic dysfunction, and hypoxemic pneumonia, and was treated in the pediatric intensive care unit with intravenous artesunate followed by oral artemether-lumefantrine...This case report describes a child with severe falciparum malaria successfully treated with intravenous artesunate who subsequently developed PADH. It illustrates the biphasic course of artemisinin therapy - initial parasite clearance followed by delayed hemolysis - underscoring the need for post-discharge monitoring."

Journal • Acute Kidney Injury • Critical care • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Malaria • Nephrology • Pediatrics • Pneumonia • Renal Disease • Respiratory Diseases • Thrombocytopenia • HP

Severe Malaria Due to Plasmodium vivax With Pulmonary Involvement: A Case Report. (PubMed, Cureus) - "Due to the unavailability of IV artesunate, treatment was initiated with artemether-lumefantrine and doxycycline, resulting in progressive improvement and successful oxygen weaning. By the third day of treatment, parasitemia had cleared. This case underscores the need for high clinical suspicion for P. vivax malaria in patients with relevant epidemiological exposure."

Journal • Critical care • Fatigue • Hematological Disorders • Infectious Disease • Malaria • Thrombocytopenia

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum and vivax malaria in Eritrea in 2024 (ANZCTR) - P4 | N=480 | Completed | Sponsor: Ministry of Health

New P4 trial • Infectious Disease • Malaria

Asymptomatic malaria: a hidden reservoir for the transmission and circulation of artemisinin partial-resistant Plasmodium falciparum in Tanzania. (PubMed, Emerg Microbes Infect) - "Artemether-lumefantrine (AL, 64.7%) was the most commonly used antimalarial in high-transmission areas, whereas sulfadoxine-pyrimethamine (SP, 75.9%) predominated in low-transmission areas. Higher AL use correlated with increased pfmdr1 mutation prevalence in high-transmission regions, while NFD detection in low-transmission areas may reflect gene flow from high-transmission settings. These findings demonstrate that asymptomatic carriers are a substantial hidden reservoir of ART-resistant parasites, emphasizing the importance of integrating molecular surveillance and demographic information on asymptomatic infections into malaria control programs to detect emerging resistance and guide targeted interventions in Tanzania."

Journal • Infectious Disease • Malaria • ABCB1

Novel Pfk13 and Pfubp1 genotypes in African Plasmodium falciparum isolates exhibiting reduced susceptibility to the antimalarials artemisinin and lumefantrine. (PubMed, mBio) - "Recent evidence indicates that the clinical efficacy of the antimalarial combination artemether-lumefantrine may be compromised by emerging Plasmodium falciparum populations with reduced susceptibility to both components in some parts of East Africa...In this study, we present new assessments of the effectiveness of the major drugs in use against such parasites and link these findings to the genetic profiles of the parasites causing each infection. We identify new genetic types in some of these patient samples that may provide new markers for monitoring malaria drug resistance in African communities."

Journal • Infectious Disease • Malaria • FUBP1

Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Curtin University

New P4 trial • Infectious Disease • Malaria

Efficacy of artemether lumefantrine vs chloroquine for the treatment of Plasmodium Vivax infection in Pakistan. (PubMed, Sci Rep) - No abstract available

Journal • Infectious Disease

Impacts of Seasonal Mass Drug Administration in School-Aged Children on Chronic Malaria Infections in Burkina Faso. (PubMed, Am J Trop Med Hyg) - "Monthly parasitological surveys were conducted in Burkina Faso rural localities during the dry season targeting two cohorts of school-aged children: one of children uninfected at baseline who received no treatment and another of parasitemic asymptomatic children who received a full treatment dose of artemether-lumefantrine...msp1/msp2 genotyping revealed the same haplotypes over time within participants, and analysis of drug-resistance markers showed low frequencies of mutations associated with antimalarial resistance. Our findings demonstrated that malaria transmission is interrupted during the dry season and that early MDA can effectively prevent infection, with over 90% of participants remaining parasite free, highlighting its potential to disrupt transmission dynamics."

Journal • Infectious Disease • Malaria • ABCB1

Antimalarial efficacy of aqueous crude rootbark extracts of Zanthoxylum Chalybeum: An in vivo experimental study in Wistar Albino Mice infected with Plasmodium berghei. (PubMed, Res Sq) - "The positive control (B) received Artemether-Lumefantrine at 4mg/kg body weight, and group C (the negative control) was given distilled water used to dilute the rootbark extracts at a dose of 10mL/kg...Conclusion Z. chalybeum showed efficacy in parasite clearance and maintaining the body temperature of Wistar albino mice infected with P. berghei . Additional studies should be done to determine the anti-plasmodial and anti-pyretic mechanisms of Z. chalybeum root bark extracts."

Journal • Preclinical • Infectious Disease • Malaria

OPTIMAH: OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (clinicaltrials.gov) - P4 | N=380 | Recruiting | Sponsor: Yale University | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • Malaria

Evaluation of Antimalarial Activity of Senna alata and Influence on Hepatic Caspase-3 and Nuclear Factor Keppa B. (PubMed, Parasite Immunol) - "Group 5 served as the standard drug control that received 20 mg/kg of LonartDS (artemether-lumefantrine)...Put together, the demonstrated antimalarial activity of EESa protected the liver from the inflammatory and apoptotic damages caused by malarial infection in experimental mice. This study supports the use of S. alata in the traditional treatment of malaria."

Journal • Hematological Disorders • Infectious Disease • Inflammation • Malaria • CASP3 • NFKB1

Pediatric Mixed Plasmodium vivax-P. falciparum Infection with Disparate Parasitemias: Diagnostic and Surveillance Challenges. (PubMed, Children (Basel)) - "Following confirmation of normal glucose-6-phosphate dehydrogenase activity, treatment with artemether-lumefantrine was initiated, followed by primaquine for hypnozoite eradication. It also underscores surveillance limitations that can misclassify mixed infections, potentially affecting epidemiological estimates and treatment strategies. Timely recognition and comprehensive diagnostic evaluation are essential to ensure appropriate antimalarial therapy, prevent complications, and inform public health interventions in regions where both species coexist."

Journal • Infectious Disease • Malaria • Pediatrics

The Effect of Artemether-Lumefantrine Combined with a Single Dose of Primaquine on Plasmodium falciparum Gametocyte Clearance and Post-Treatment Infectivity to Anopheles arabiensis. (PubMed, Trop Med Infect Dis) - "High baseline gametocyte density strongly correlated with increased infectivity. Adding SLD-PQ markedly accelerates gametocyte clearance and completely blocks post-treatment transmission. Submicroscopic gametocytemia contributed to residual transmission in the AL-only group. Incorporation of SLD-PQ alongside AL, in line with WHO recommendations, is advised to enhance post-treatment transmission blocking, with continued surveillance."

Journal • Infectious Disease • Malaria

Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya (clinicaltrials.gov) - P=N/A | N=316 | Completed | Sponsor: Strathmore University

New trial • Infectious Disease • Malaria

Therapeutic efficacy of dihydroartemisinin-piperaquine and artesunate-pyronaridine combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Ghana, 2023. (PubMed, Front Public Health) - "Currently, artesunate-amodiaquine (AS-AQ), artemetherlumefantrine (AL), and artesunate-pyronaridine (AP) are the first-line medicines for treating uncomplicated malaria whilst dihydroartemisinin-piperaquine (DHAP) is the second-line medicine. We conclude that the therapeutic efficacy level of DHAP has remained high (>90%) since the baseline study in 2020/2021. Also, the baseline efficacy level of AP is high (>90%) warranting the use of both DHAP and AP in the treatment of uncomplicated malaria in the country."

Journal • Hematological Disorders • Infectious Disease • Malaria

Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women (clinicaltrials.gov) - P=N/A | N=3300 | Completed | Sponsor: Noguchi Memorial Institute for Medical Research

New trial • Infectious Disease • Malaria

Prevalence of antimalarial drug resistance molecular markers in Makenene, central Cameroon. (PubMed, Int J Parasitol Drugs Drug Resist) - "The in-depth analysis of genetic mutations associated with antimalarials resistance in this study, notably those with a high prevalence of mutations on the Pfdhfr and Pfdhps genes, highlights the immediate need for proactive strategies to combat resistance in Makenene. Continuous monitoring, including molecular and in vivo surveillance is crucial to uphold the effectiveness of current treatments and, more particularly, artemisinin-based combination therapies, and to enable better decision-making on effective treatment policy in Cameroon and in Africa as a whole."

Biomarker • Journal • Infectious Disease • Malaria • ABCB1

Spleen protective role, Antiplasmodial and Antioxidant activity of Polyalthia longifolia in mice infected with Plasmodium berghei parasite. (PubMed, Vet Anim Sci) - "Graded doses (100, 200 and 400 mg/kg/day) of ethanol extract of P. longifolia (EEPL) leaves and standard drug, Artemether and Lumefantrine (lonart) (2 mg/kg/day) were used for the treatment of malaria mice...In conclusion, EEPL treatment was able to control the macrophage response of mice erythrocytes infected with P. berghei. To pinpoint the exact mechanism causing these alterations, more research, such as characterizing the bioactive chemicals, might be required."

Journal • Preclinical • Infectious Disease • Malaria

Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV). (PubMed, EClinicalMedicine) - P3 | "Several antimalarials exhibit antiviral activity against SARS-CoV-2 in vitro and have been suggested as potential therapeutic candidates for COVID-19, particularly pyronaridine-artesunate (PA), despite disappointing clinical results with chloroquine and hydroxychloroquine. Both treatments were highly effective as antimalarials and should continue to be considered first- or second-line treatment options for uncomplicated malaria in patients with mild to moderate COVID-19. Gates Foundation."

Journal • Infectious Disease • Malaria • Novel Coronavirus Disease • Respiratory Diseases

Treatment Failure and Post-Artesunate Delayed Haemolysis in a Returned Traveller From Uganda With Partially Drug-Resistant Severe Plasmodium falciparum Malaria. (PubMed, Med J Aust) - "He received intravenous artesunate followed by artemether-lumefantrine...Further testing for drug-resistant phenotypes and genotypes demonstrated reduced susceptibility to lumefantrine, an A675V mutation in the pfk13 gene and increased ring-stage survival, consistent with partial artemisinin resistance. The case highlights the high risk of P. falciparum treatment failure in patients with hyperparasitaemia and partial drug resistance."

Journal • Hematological Disorders • Infectious Disease • Malaria